

Sarepta Therapeutics to Present Company Overview at the 2015 Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 10, 2015-- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that management will be presenting a company overview and update at the 2015 Morgan Stanley Global Healthcare Conference in New York, NY. Edward Kaye, Sarepta's interim chief executive officer and chief medical officer, will represent the company in a fireside chat on Thursday, September 17 at 4:40 PM Eastern Time.

The fireside chat will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the *Events and Presentations* section following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. For more information, please visit us at www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Media and Investors:

Sarepta Therapeutics, Inc.

Ian Estepan, 617-274-4052

iestepan@sarepta.com

or

W2O Group

Ryan Flinn, 415-946-1059

Mobile: 510-207-7616

rflinn@w2ogroup.com